Neil Stahl - Regeneron Pharmaceuticals Insider

REGN -- USA Stock  

USD 367.44  1.46  0.40%

Executive VP of RandD
Dr. Neil Stahl, Ph.D., is an Executive Vice President Research and Development Sciences of the Company. He previously served as Senior Vice President, Research and Development Sciences from January 2007 to December 2014, as Senior Vice President, Preclinical Development and Biomolecular Sciences from December 2000 to December 2007, and as Vice President, Preclinical Development and Biomolecular Sciences from January 2000 to December 2000. He joined the Company in 1991. Before becoming Vice President, Biomolecular Sciences in July 1997, Dr. Stahl was Director, Cytokines and Signal Transduction
Age: 60  EVP Since 2014  Ph.D    
914-847-7000  http://www.regeneron.com
Stahl received his Ph.D. in Biochemistry from Brandeis University.

Neil Stahl Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 16.12 % which means that it generated profit of $16.12 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.97 % meaning that it created $24.97 on every $100 dollars invested by stockholders.
The company currently holds 704.64 M in liabilities with Debt to Equity (D/E) ratio of 10.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.52 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 6401 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA. It is located in NEW YORK U.S.A and employs 6,401 people. Regeneron Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Director
Joseph Goldstein, Director, Ph.D
Anthony Coles, Director
George Sing, Director
Peter Powchik, President
Jay Markowitz, President
Robert Terifay, SVP
Robert Landry, CFO
Michael Brown, Director, Ph.D
Christine Poon, Director
Neil Stahl, EVP, Ph.D
Marion McCourt, President
George Yancopoulos, President
Huda Zoghbi, Director, Ph.D
Bonnie Bassler, Director
Joseph LaRosa, President
Daniel Plew, President, MBA
Leonard Schleifer, CEO, Ph.D
Alfred Gilman, Director, Ph.D
Roy Vagelos, Chairman, Ph.D
Michael Aberman, President, MBA
Manisha Narasimhan, Executive
Douglas McCorkle, President
Marc TessierLavigne, Director, Ph.D
Christopher Fenimore, President, MBA
Arthur Ryan, Director

Stock Performance Indicators

Did you try this?

Run Fundamentals Matrix Now
   

Fundamentals Matrix

View fundamentals matrix and analyze how accounts are interrelated and interconnected with each other
All  Next Launch Fundamentals Matrix
Currently Active Assets on Macroaxis
BND   
Purchased few shares of
few hours ago
Traded for 79.19
QQQ   
Purchased few shares of
few hours ago
Traded for 179.93
SPY   
Purchased few shares of
few hours ago
Traded for 281.04
TRP   
Sold one share of
few hours ago
Traded for 42.84
KO   
Purchased over 90 shares of
few hours ago
Traded for 45.12
Additionally take a look at Your Equity Center. Please also try Portfolio Reporting module to create custom reports across your portfolios and generate quick suggestion pitch.